What Does Kenvue (KVUE) Do? — Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters at a Glance
Kenvue (KVUE) is the company behind global consumer health brands such as Tylenol, Listerine, Neutrogena, Johnson's, and Aveeno, and stands as a US-listed household-products stock where stable consumer-staples revenue is paired with global brand power.
🏢 What kind of company is Kenvue?
Kenvue (KVUE) is a US-headquartered global consumer health specialist. It has operated as an independent publicly listed company since the spin-off of Johnson & Johnson's (JNJ) consumer health business, running a portfolio of brands spanning pain relief, oral care, skin care, baby care, and adhesive bandages.
Its integrated consumer health model rests on three major pillars: Self Care (OTC brands such as Tylenol and Nicorette), Skin Health & Beauty (dermo-cosmetic brands such as Neutrogena and Aveeno), and Essential Health (everyday-care brands such as Johnson's, Band-Aid, and Listerine). It is a core player in the global consumer health category.
How does Kenvue make money?| Business Segment | Revenue Mix | Description |
|---|---|---|
| Self Care | Core | Revenue from over-the-counter pharmaceutical brands such as Tylenol and Nicorette |
| Skin Health & Beauty | Key growth pillar | Dermo-cosmetic brands such as Neutrogena and Aveeno |
| Essential Health | Diversification pillar | Everyday-care brands such as Johnson's, Band-Aid, and Listerine |
Self Care and Skin Health & Beauty form the two largest revenue pillars, while Essential Health functions as the stable revenue backbone of everyday consumer staples. Brand recognition and shelf presence across pharmacy and retail channels are central to revenue stability, producing a structure that maintains a degree of revenue resilience through cycles and consumer-spending shifts. Margins fluctuate in line with raw-material costs, FX, and the new-product launch cadence.
📐 Kenvue's market cap and corporate scale
The company's market capitalization stands at $38.0B, with 22,000명 employees.
It ranks among the top consumer health specialists by market cap within the global household and personal-care category, and is grouped alongside fellow global consumer-staples peers such as PG (Procter & Gamble), CL (Colgate-Palmolive), and CHD (Church & Dwight). Backed by global-scale free cash flow, it maintains a capital-return policy that combines quarterly dividends with share repurchases.
📈 Kenvue outlook and share-price trends
Recovery in global consumer health demand, expansion in emerging markets, and a strengthened dermo-cosmetic and self-care brand lineup are the medium- to long-term growth drivers. Brand recognition and stable everyday-staples revenue are the core of revenue resilience, while efficiencies in raw materials and production also feed into margin improvement. In the near term, FX exposure, occasional quarterly revenue slowdowns, raw-material cost swings, and broader global consumer-spending softness can act as sources of volatility.
- Recovery in global consumer health demand
- Expansion in emerging markets
- Strengthening of the dermo-cosmetic and self-care brand lineup
⚔️ Kenvue's core strengths and risks
Global brand recognition, strong shelf positioning across pharmacy and retail channels, and a diversified category portfolio are its strengths, while FX exposure and a broader consumer-spending slowdown are the core risks.
💪 Core Strengths
⚠️ Core Risks
🔄 Kenvue's competitors and related (beneficiary) stocks
Direct competitors include other players in the household and personal-care category such as PG (Procter & Gamble), CL (Colgate-Palmolive), and CHD (Church & Dwight). On the related-stock side, the former parent JNJ (Johnson & Johnson), tissue and household-products company KMB (Kimberly-Clark), and cosmetics and beauty player EL (Estee Lauder) sit within the same broader consumer-staples flow.
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
| PG | Procter & Gamble Co | $146.10 | -1.9% | $340.2B | 21.4 | 6.3 | 31.12% | 3.04% |
| CL | Colgate-Palmolive Co | $93.49 | +0.8% | $74.8B | 36.3 | 515.9 | 821.65% | 2.27% |
| Church & Dwight Co Inc | $99.86 | -0.1% | $23.7B | 32.9 | 5.7 | 16.78% | 1.24% |
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | $265.53 | -0.5% | $639.9B | 30.8 | 7.5 | 25.74% | 2.02% |
| KMB | Kimberly-Clark Corp | $113.23 | +0.1% | $37.6B | 17.8 | 20.9 | 118.81% | 4.58% |
| EL | Estee Lauder Cos. Inc | $84.13 | -0.7% | $30.4B | - | 7.6 | -5.95% | 1.71% |
✅ Checklist for Kenvue investors
Key items to monitor when investing in Kenvue. Global consumer health demand, the FX environment, the revenue trajectory of dermo-cosmetic and self-care brands, and the capital-return policy are the key short- and medium-term variables.
| Checkpoint | What to Verify | Current Status |
|---|---|---|
| 🧴 Brand Revenue | Growth rate of core brand revenue | Steady trend |
| 💱 FX Exposure | Impact of FX moves on translated revenue | Worth monitoring |
| 🌍 Emerging-Market Expansion | Revenue trends in emerging markets | Increasing trend |
| 💰 Capital Return | Quarterly dividend and share repurchase policy | Consistent return flow |
During global economic downturns, revenue softness can appear in selected categories. FX swings can affect the translation of global revenue, while raw-material and logistics cost variation along with price competition against retailer private-label brands are near-term margin risks.
As a core player in the global consumer health category, Kenvue is a core household-products stock that combines a portfolio of category-defining brands with stable consumer-staples revenue. Global demand and the FX environment are the key variables to monitor, and a phased buying approach with a long-term horizon is recommended.
이 글은 2026년 5월 21일 기준 정보입니다.